I think it's closer to a $250 stock if a buyout doesn't happen and we wait for IMGN853 to come to market. The fact that Kadcyla works *at all* against any kind of metastatic cancer with _minimal_ side effects speaks volumes of the kind of transformative new paradigm that is ADC technology.
The company seems very focused on 529, the B-Cell market is Huge. I hate to bring up Genta, but they had a an antisense compound that was supposed to work on b-cell (prevent resistance to chemo) and the GNTA CEO claimed that product would work "in everything and with everything", he was talking all cancer types. Ray Warrell was prone to exaggeration.
853 also looks very interesting. If either is a winner shareholders will do very well, if both are winners we could be talking $100-200+ in 3-5+ years if not acquired sooner. They need to accelerate both of these compounds.